Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture - Wikidata - awgldk - TriplyDB

Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture

Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture

http://www.wikidata.org/entity/Q24626477

about

Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin Amyloidosis Amyloid formation in light chain amyloidosis A loss of FUS/TLS function leads to impaired cellular proliferation Amitriptyline-mediated cognitive enhancement in aged 3×Tg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity Human-murine transthyretin heterotetramers are kinetically stable and non-amyloidogenic. A lesson in the generation of transgenic models of diseases involving oligomeric proteins A Substructure Combination Strategy To Create Potent and Selective Transthyretin Kinetic Stabilizers That Prevent Amyloidogenesis and Cytotoxicity Chemoselective small molecules that covalently modify one lysine in a non-enzyme protein in plasma Potent Kinetic Stabilizers That Prevent Transthyretin-Mediated Cardiomyocyte Proteotoxicity Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade Bifunctional coumarin derivatives that inhibit transthyretin amyloidogenesis and serve as fluorescent transthyretin folding sensors Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out The rate and equilibrium constants for a multistep reaction sequence for the aggregation of superoxide dismutase in amyotrophic lateral sclerosis The flavonoid luteolin, but not luteolin-7-O-glucoside, prevents a transthyretin mediated toxic response Tetrabromobisphenol A Is an Efficient Stabilizer of the Transthyretin Tetramer Amyloid oligomer conformation in a group of natively folded proteins.Insights into the role of the beta-2 microglobulin D-strand in amyloid propensity revealed by mass spectrometry Physiological IgM class catalytic antibodies selective for transthyretin amyloid.Proteomic analysis of peritoneal fluid of patients treated by peritoneal dialysis: effect of glucose concentration.Differential expression of Cathepsin E in transthyretin amyloidosis: from neuropathology to the immune system.Raft lipids as common components of human extracellular amyloid fibrils.Uptake of aggregating transthyretin by fat body in a Drosophila model for TTR-associated amyloidosis.Intrinsic determinants of neurotoxic aggregate formation by the amyloid beta peptide Aqueous humor erythropoietin levels in open-angle glaucoma patients with and without TTR V30M familial amyloid polyneuropathy.Designed α-sheet peptides inhibit amyloid formation by targeting toxic oligomers.Drusen deposits associated with aging and age-related macular degeneration contain nonfibrillar amyloid oligomers.Interleukin-1 signaling pathway as a therapeutic target in transthyretin amyloidosis.Initial conformational changes of human transthyretin under partially denaturing conditions Quantification of quaternary structure stability in aggregation-prone proteins under physiological conditions: the transthyretin case.Distinct annular oligomers captured along the assembly and disassembly pathways of transthyretin amyloid protofibrils An overview of drugs currently under investigation for the treatment of transthyretin-related hereditary amyloidosis.Sulfated glycosaminoglycans accelerate transthyretin amyloidogenesis by quaternary structural conversion Structural study of metastable amyloidogenic protein oligomers by photo-induced cross-linking of unmodified proteins A competition assay to identify amyloidogenesis inhibitors by monitoring the fluorescence emitted by the covalent attachment of a stilbene derivative to transthyretin.Inhibition of TTR aggregation-induced cell death--a new role for serum amyloid P component.Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis.ATF6 activation reduces the secretion and extracellular aggregation of destabilized variants of an amyloidogenic protein.TRPM8 and Nav1.8 sodium channels are required for transthyretin-induced calcium influx in growth cones of small-diameter TrkA-positive sensory neurons.Amyloidogenic and non-amyloidogenic transthyretin variants interact differently with human cardiomyocytes: insights into early events of non-fibrillar tissue damage.Amyloidosis: pathogenesis and new therapeutic options.Mechanisms of transthyretin cardiomyocyte toxicity inhibition by resveratrol analogs.

P2860

Q26764754-ACDE026A-93A0-4E06-812E-F0F8922112B2 Q27022257-DA4AFEE1-9C3C-44CA-B94C-A2BD33E29C7F Q27331026-4DB8E15A-A197-4D09-AFBD-81938457C868 Q27334070-0CB4265C-0B26-40C1-A4B7-9A3CE9F4DDCF Q27649069-99C7CAC7-6E3A-4CEB-96E1-CCB0284A1629 Q27658823-90D7A3F1-2469-44B6-A6F9-A37AB29043BB Q27659009-D0BDF7F3-C44C-4A47-9653-7BD2DB1A45C9 Q27671971-0A9A74C5-8559-461A-BBB7-84EE15CF9C69 Q27679360-2D7591FA-46A7-4608-B4A8-DA64A491059E Q27679824-244F8E54-08DD-4610-A075-518E358B07E4 Q28084013-C2AE210E-3AB6-4306-99E0-271432DCD0CE Q28287224-53CE93FF-8980-4D69-873C-F22F27B5EB4F Q28547541-E8CB9233-B558-487E-A253-29058658E8D9 Q28551432-4189E58C-DF16-4D2D-9E87-501D85EF1045 Q33370281-578F9F8D-E607-48D6-A61A-C4688E8FA250 Q33551708-D9300316-AF47-42AA-8FD3-856CC6C864B8 Q33676625-563CC557-A17A-404A-ACCC-2EF515B3CEA0 Q33747370-FE88EE7F-F28F-4031-83F8-CCD1702460EA Q33768132-13BE459A-D244-4D65-853A-D8CF10C78CF2 Q33771985-CBBDAA9A-97CD-48D5-B9B3-2BCDD4E5F4E4 Q33778710-DB3D58A3-6834-4F35-A082-288014F26E2E Q33795575-F75B7405-B748-437A-B0AB-F773C2BBBA61 Q33864879-EE49C959-B5A4-4331-BC0D-2AFD3CA5A0CF Q33878699-CE2AF660-03DE-4A05-88CB-A41507D68058 Q34331346-9EFF3A64-7917-496F-8588-AD7220620AC0 Q34336131-F6EE430C-840E-4BB6-A9F2-44B9EB891A6B Q34350522-6E869608-FAD8-43B4-9788-15A7260842EC Q34379670-C28C0686-B171-4E2C-8E46-0EBC75C579D6 Q34416296-5C83A917-15DF-4883-8080-017298749C49 Q34428314-F3E94612-A832-4095-B4EB-505F5D27A021 Q34561167-D4B57B16-8391-4416-B876-5300C12FD066 Q34574518-575AB4F9-2494-4170-8EBB-106AE8EDA877 Q34576022-2EAE0BC3-5216-4536-B606-4B6DA2EA8CAF Q34580145-A8A60D6C-AE4F-4CE8-87E1-03A2120226B7 Q34581917-3124A3C8-F13B-4FDA-8145-313D05FCF7FC Q34625989-B9845CA1-FE62-49EB-8F33-6AFCCF7D09CB Q34677515-841182A4-6531-4461-9834-5AD363CAD073 Q34951860-1322871D-BDA4-4933-973C-82641BB147DB Q35111771-CC384E0D-6DE9-4CD8-BF12-6CCB5120954F Q35133371-67D99954-6764-43EF-9417-1BD90D38E43B

P2860

Tissue damage in the amyloidoses: Transthyretin monomers and nonnative oligomers are the major cytotoxic species in tissue culture

http://www.wikidata.org/entity/Q24626477

description

2004 nî lūn-bûn

@nan

2004 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի մարտին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Tissue damage in the amyloidos ...... oxic species in tissue culture

@ast

Tissue damage in the amyloidos ...... oxic species in tissue culture

@en

Tissue damage in the amyloidos ...... oxic species in tissue culture

@nl

type

label

Tissue damage in the amyloidos ...... oxic species in tissue culture

@ast

Tissue damage in the amyloidos ...... oxic species in tissue culture

@en

Tissue damage in the amyloidos ...... oxic species in tissue culture

@nl

prefLabel

Tissue damage in the amyloidos ...... oxic species in tissue culture

@ast

Tissue damage in the amyloidos ...... oxic species in tissue culture

@en

Tissue damage in the amyloidos ...... oxic species in tissue culture

@nl

P1433

Q24626477-93552895-BBDA-42D0-815D-3D70C3A18128

P1476

Q24626477-D7EFA344-EA3F-4431-B361-238CF97C5C98

P2093

Q24626477-D02DE118-67BA-46CE-BAC5-855C7544A72C

Q24626477-FB7A04B0-F572-4ED9-9BC8-E8F585CD3DBE

P2860

Q24626477-025805BE-F154-448D-9177-271178090CD4

Q24626477-157920F9-E432-43A8-94D9-55EB84217D3A

Q24626477-19E10776-4FDA-44FE-8B72-26784CF45E90

Q24626477-1CCF92D7-4E98-4D79-A5F6-1F3EB19C24FD

Q24626477-26FD90A7-504D-4441-8E3A-E3938E718F2D

Q24626477-2F5B5BA6-7ACF-4CBE-A61C-8D104195FDBA

Q24626477-57DFFD64-7AB9-4C73-ABDE-79FD849836AB

Q24626477-5A6BD356-3E71-438E-94C8-A0BCF20186E4

Q24626477-6F2AC444-3DA5-4C68-873D-FE4F528353E8

Q24626477-7AD08091-A2CA-4A67-BE09-1DE2A9E7B0BF

P304

Q24626477-8A43D360-556A-472F-8359-51F4E3576993

P31

Q24626477-304774F1-FB08-4DA8-8301-59772DDEB3E1

P3181

Q24626477-DAA3FF4D-66A7-41C2-B9A2-E207B319393C

P356

Q24626477-22316734-C8D0-496D-A237-C6B856EBF687

P407

Q24626477-D58D41EF-6CCD-43F9-A729-3F24A2189A45

P433

Q24626477-864E9851-3A6B-4D96-9A6D-1159617E44B1

P478

Q24626477-047CF0EC-D313-4D95-AF3B-61358C92270A

P50

Q24626477-6E38F772-F092-4D51-AA09-3B738CCD9988

Q24626477-C5A611CF-347D-4FDB-BE02-D1A93AA16F32

Q24626477-F1349A75-6D7B-4783-9011-BD1988DD71B9

P577

Q24626477-4386D271-5C1B-404E-B2C4-01E459469540

P5875

Q24626477-2E2CDF80-82C5-46B5-8489-D266625163C9

P698

Q24626477-0666D152-2A07-4EA2-B476-73281B21E4C8

P921

Q24626477-190D01BD-3A21-41EA-AC57-FCEB4CB11657

P932

Q24626477-0AFECD25-CFD3-488E-87DC-9A8F39C765B2

P3181

P356

PNAS.0400062101

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Tissue damage in the amyloidos ...... oxic species in tissue culture

@en

P2093

Songpon Deechongkit

http://www.w3.org/2001/XMLSchema#string

Xin Jiang

http://www.w3.org/2001/XMLSchema#string

P2860

Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates

Rational design of potent human transthyretin amyloid disease inhibitors

An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured

Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis

The genetics of the amyloidoses.

Support for the multigenic hypothesis of amyloidosis: the binding stoichiometry of retinol-binding protein, vitamin A, and thyroid hormone influences transthyretin amyloidogenicity in vitro.

Review: TTR amyloidosis-structural features leading to protein aggregation and their implications on therapeutic strategies.

Prevention of transthyretin amyloid disease by changing protein misfolding energetics.

D18G transthyretin is monomeric, aggregation prone, and not detectable in plasma and cerebrospinal fluid: a prescription for central nervous system amyloidosis?

Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.

P304

2817-22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

2230476

http://www.w3.org/2001/XMLSchema#string

P356

10.1073/PNAS.0400062101

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

101

http://www.w3.org/2001/XMLSchema#string

P50

Natàlia Reixach

Jeffery W. Kelly

P577

2004-03-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

5248537

http://www.w3.org/2001/XMLSchema#string

P698

14981241

http://www.w3.org/2001/XMLSchema#string

P921

P932

365703

http://www.w3.org/2001/XMLSchema#string